{"id":"W4414335360","doi":"10.1016/s0140-6736(25)01576-4","title":"Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"York University; Probity Medical Research; Dermatrials Research; Innovaderm (Canada)","funders":"Johnson and Johnson","keywords":"Plaque psoriasis; Placebo; Clinical trial; Psoriasis; Oral cavity; Oral administration","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002347038,0.002331585,0.005450781,0.0006069252,0.0005584246,0.001405704,0.001287824,0.003105617,0.007840172],"category_scores_gemma":[0.002327346,0.001109967,0.003763039,0.0005099475,0.001283234,0.001843594,0.0004890139,0.004106638,0.001477419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009057981,"about_ca_system_score_gemma":0.0009044627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001463598,"about_ca_topic_score_gemma":0.003235116,"domain_scores_codex":[0.9990758,0.0003838975,0.00008499981,0.0002100484,0.00007808446,0.00016714],"domain_scores_gemma":[0.9989656,0.0003134184,0.0002515874,0.00007629138,0.00008427887,0.0003087833],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9837366,0.001974868,0.0001744246,0.001321082,0.001300016,0.00002016282,0.00004210377,0.0001057265,0.001471393,0.00006349111,0.0004802219,0.009309985],"study_design_scores_gemma":[0.9633389,0.03373612,0.0009169955,0.0000690628,0.0009561999,0.00002587751,0.00003346469,0.000150927,0.0002173853,0.000133481,0.0004032906,0.00001836791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.952943,0.03169296,0.001191312,0.001449337,0.001998081,0.004715475,0.001629981,0.0004119655,0.003967829],"genre_scores_gemma":[0.9806652,0.008397801,0.001574157,0.001303227,0.000675649,0.002703444,0.000878418,0.00004398656,0.003758105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007840172,"threshold_uncertainty_score":0.02622801,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06560107486122974,"score_gpt":0.3448904829824075,"score_spread":0.2792894081211778,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}